Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I

Natural killer (NK) cell-based treatments are promising therapies for multiple myeloma (MM). Carfilzomib (CFZ), is a second-generation proteasome inhibitor, used to treat relapsed and refractory MM. In this study, we determined that CFZ treatment enhanced the sensitivity of MM cells to NK cell-media...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Guang, Gao, Minjie, Zhang, Yiwen, Kong, Yuanyuan, Gao, Lu, Tao, Yi, Han, Ying, Wu, Huiqun, Meng, Xiuqin, Xu, Hongwei, Zhan, Fenghuang, Wu, Xiaosong, Shi, Jumei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694968/
https://www.ncbi.nlm.nih.gov/pubmed/26323098

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694968/
https://www.ncbi.nlm.nih.gov/pubmed/26323098

Ejemplares similares